摘要
目的:探讨信迪利单抗联合呋喹替尼在微卫星稳定型(microsatellite stable,MSS)晚期结肠癌中的应用效果。方法:根据随机数字表法将蚌埠医科大学第一附属医院于2021年10月-2023年10月收治的100例MSS晚期结肠癌患者分为接受呋喹替尼治疗的对照组(n=50)和接受呋喹替尼联合信迪利单抗治疗的观察组(n=50),比较两组临床疗效、免疫功能、血管新生指标、不良反应及1年生存率。结果:观察组治疗总有效率高于对照组(P<0.05);治疗后,两组辅助性T细胞、IgA、IgG较治疗前降低,但观察组更高,差异有统计学意义(P<0.05),两组血管内皮生长因子、转化生长因子-β_(1)较治疗前降低,且观察组更低,差异有统计学意义(P<0.05);两组各不良反应发生率比较差异无统计学意义(P>0.05);观察组1年生存率为90.00%(45/50),高于对照组的62.00%(31/50)(χ^(2)=10.746,P=0.001)。结论:与呋喹替尼单药治疗相比,信迪利单抗联合呋喹替尼治疗MSS晚期结肠癌可显著提升临床效果,减轻对免疫功能的影响,有效减少肿瘤血管生成,并能提升1年生存率,具有一定安全性。
Objective:To investigate the application effect of Sintilimab combined with Fruquintinib in microsatellite stable(MSS)advanced colon cancer.Method:According to the random number table method,100 patients with MSS advanced colon cancer admitted to the First Affiliated Hospital of Bengbu Medical University from October 2021 to October 2023 were divided into a control group(n=50)receiving Fruquintinib treatment and an observation group(n=50)receiving Fruquintinib combined with Sintilimab treatment.The clinical efficacy,immune function,angiogenesis index,adverse reactions and 1-year survival rate of the two groups were compared.Result:The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,levels of helper T cells,IgA,IgG decreased in both groups compared to before the treatment,but the observation group showed higher levels than the control group,the differences were statistically significant(P<0.05),vascular endothelial growth factor and transforming growth factor-β_(1) decreased in both groups compared to before the treatment,and the observation group showed lower levels than the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions between the two groups were not significantly different(P>0.05).The 1-year survival rate of the observation group was 90.00%(45/50),which was higher than 62.00%(31/50)of the control group(χ^(2)=10.746,P=0.001).Conclusion:Compared with Fruquintinib monotherapy,the combination of Sintilimab and Fruquintinib can significantly improve clinical efficacy in patients with MSS advanced colorectal cancer,and can reduce the impact on immune function,effectively reduce tumor angiogenesis,and improve the 1-year survival rate,with certain safety.
作者
柳亚魁
LIU Yakui(Department of Gastrointestinal Surgery,the First Affiliated Hospital of Bengbu Medical University,Bengbu 233004,China)
出处
《中国医学创新》
2025年第23期45-49,共5页
Medical Innovation of China
基金
2021年度蚌埠医学院科技项目(2021byzd145)。
关键词
信迪利单抗
呋喹替尼
晚期结肠癌
微卫星稳定型
血管新生
Sintilimab
Fruquintinib
Advanced colorectal carcinoma
Microsatellite stable
Angiogenesis
